{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:28:19Z","timestamp":1792632499387,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"20","funder":[{"DOI":"10.13039\/100000002","name":"National Institute for Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,21]]},"abstract":"<jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To determine the clinical impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a)\u2009&amp;gt;\u2009500\u2009mg\/L on the primary end point of quantitative myocardial perfusion, as well as secondary end points including atheroma burden, exercise capacity, symptoms, and quality of life.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a single-blinded randomized controlled trial in 20 patients with refractory angina and raised lipoprotein(a)\u2009&amp;gt;\u2009500\u2009mg\/L, with 3\u2009months of blinded weekly lipoprotein apheresis or sham, followed by crossover. The primary endpoint was change in quantitative myocardial perfusion reserve (MPR) assessed by cardiovascular magnetic resonance. Secondary endpoints included measures of atheroma burden, exercise capacity, symptoms and quality of life.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The primary endpoint, namely MPR, increased following apheresis (0.47; 95% CI 0.31\u20130.63) compared with sham (\u22120.16; 95% CI\u2009\u2212\u20090.33\u20130.02) yielding a net treatment increase of 0.63 (95% CI 0.37\u20130.89; P\u2009&amp;lt;\u20090.001 between groups). Improvements with apheresis compared with sham also occurred in atherosclerotic burden as assessed by total carotid wall volume (P\u2009&amp;lt;\u20090.001), exercise capacity by the 6\u2009min walk test (P\u2009=\u20090.001), 4 of 5 domains of the Seattle angina questionnaire (all P\u2009&amp;lt;\u20090.02) and quality of life physical component summary by the short form 36 survey (P\u2009=\u20090.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Lipoprotein apheresis may represent an effective novel treatment for patients with refractory angina and raised lipoprotein(a) improving myocardial perfusion, atheroma burden, exercise capacity and symptoms.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehx178","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T04:34:15Z","timestamp":1490243655000},"page":"1561-1569","source":"Crossref","is-referenced-by-count":97,"title":["Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial"],"prefix":"10.1093","volume":"38","author":[{"given":"Tina Z.","family":"Khan","sequence":"first","affiliation":[{"name":"1NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3\u20096NP, UK"},{"name":"2National Heart and Lung Institute, Imperial College, Sydney Street, London SW3 6NP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yueh","family":"Hsu","sequence":"additional","affiliation":[{"name":"3National Heart, Lung and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Arai","sequence":"additional","affiliation":[{"name":"3National Heart, Lung and Blood Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Rhodes","sequence":"additional","affiliation":[{"name":"1NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3\u20096NP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Pottle","sequence":"additional","affiliation":[{"name":"1NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3\u20096NP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Wage","sequence":"additional","affiliation":[{"name":"1NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3\u20096NP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston","family":"Banya","sequence":"additional","affiliation":[{"name":"1NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3\u20096NP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Gatehouse","sequence":"additional","affiliation":[{"name":"1NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3\u20096NP, UK"},{"name":"2National Heart and Lung Institute, Imperial College, Sydney Street, London SW3 6NP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivraman","family":"Giri","sequence":"additional","affiliation":[{"name":"4Siemens Healthcare, 737 North Michigan Ave, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Collins","sequence":"additional","affiliation":[{"name":"1NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3\u20096NP, UK"},{"name":"2National Heart and Lung Institute, Imperial College, Sydney Street, London SW3 6NP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dudley J.","family":"Pennell","sequence":"additional","affiliation":[{"name":"1NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3\u20096NP, UK"},{"name":"2National Heart and Lung Institute, Imperial College, Sydney Street, London SW3 6NP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Barbir","sequence":"additional","affiliation":[{"name":"1NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3\u20096NP, UK"},{"name":"2National Heart and Lung Institute, Imperial College, Sydney Street, London SW3 6NP, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,4,26]]},"reference":[{"key":"2022102606370370000_ehx178-B1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/euhj.2001.2706","article-title":"The problem of chronic refractory angina; report from the ESC joint study group on the treatment of refractory angina","volume":"23","author":"Mannheimer","year":"2002","journal-title":"Eur Heart J"},{"key":"2022102606370370000_ehx178-B2","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1093\/eurheartj\/eht165","article-title":"Long-term survival in patients with refractory angina","volume":"34","author":"Henry","year":"2013","journal-title":"Eur Heart J"},{"key":"2022102606370370000_ehx178-B3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man: the Lp system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"key":"2022102606370370000_ehx178-B4","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"2022102606370370000_ehx178-B5","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2362.1994.tb02373.x","article-title":"Lipoprotein(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS)","volume":"24","author":"Cremer","year":"1994","journal-title":"Eur J Clin Invest"},{"key":"2022102606370370000_ehx178-B6","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","article-title":"Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies","volume":"102","author":"Danesh","year":"2000","journal-title":"Circulation"},{"key":"2022102606370370000_ehx178-B7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.transci.2009.05.014","article-title":"Comparison of different Lp(a) elimination techniques: a retrospective evaluation","volume":"41","author":"Borberg","year":"2009","journal-title":"Trans Apheres Sci"},{"key":"2022102606370370000_ehx178-B8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.5339\/gcsp.2015.28","article-title":"High prevalence of raised lipoprotein(a) in patients with refractory angina","volume":"2","author":"Khan","year":"2015","journal-title":"Glob Cardiol Sci Pract"},{"key":"2022102606370370000_ehx178-B9","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease. Prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"key":"2022102606370370000_ehx178-B10","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"2022102606370370000_ehx178-B11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1744-9987.2009.00667.x","article-title":"Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress\/rest perfusion magnetic resonance imaging","volume":"13","author":"Bohl","year":"2009","journal-title":"Ther Apher Dial"},{"key":"2022102606370370000_ehx178-B12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosissup.2012.10.015","article-title":"Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography","volume":"14","author":"Safarova","year":"2013","journal-title":"Atheroscler Suppl"},{"key":"2022102606370370000_ehx178-B13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jacl.2011.11.003","article-title":"Low-density lipoprotein apheresis is effective in reducing lipoprotein(a) levels and in improving symptoms in a patient with refractory angina secondary to accelerated coronary artery disease","volume":"6","author":"Ibrahim","year":"2012","journal-title":"J Clin Lipidol"},{"key":"2022102606370370000_ehx178-B14","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehq010","article-title":"Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events","volume":"31","author":"Rubinshtein","year":"2010","journal-title":"Eur Heart J"},{"key":"2022102606370370000_ehx178-B15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.atherosclerosis.2008.02.009","article-title":"Recommendations for the use of LDL apheresis","volume":"198","author":"Thompson","year":"2008","journal-title":"Atherosclerosis"},{"key":"2022102606370370000_ehx178-B16","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/j.jacc.2007.03.028","article-title":"Cardiovascular magnetic resonance perfusion imaging at 3-Tesla for the detection of coronary artery disease: a comparison with 1.5-tesla","volume":"49","author":"Cheng","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2022102606370370000_ehx178-B17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jmri.20054","article-title":"Accurate assessment of the arterial input function during high-dose myocardial perfusion cardiovascular magnetic resonance","volume":"20","author":"Gatehouse","year":"2004","journal-title":"J Magn Reson Imaging"},{"key":"2022102606370370000_ehx178-B18","first-page":"187","article-title":"Interstudy reproducibility of three-dimensional volume-selective fast spin echo magnetic resonance for quantifying carotid artery wall volume","volume":"21","author":"Varghese","year":"2005","journal-title":"J Cardiovasc Magn Reson"},{"key":"2022102606370370000_ehx178-B19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1532-429X-15-91","article-title":"Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update","volume":"15","author":"Kramer","year":"2013","journal-title":"J Cardiovasc Magn Reson"},{"key":"2022102606370370000_ehx178-B20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jcmg.2011.07.013","article-title":"A quantitative pixel-wise measurement of myocardial blood flow by contrast-enhanced first-pass CMR perfusion imaging: microsphere validation in dogs and feasibility study in humans","volume":"5","author":"Hsu","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022102606370370000_ehx178-B21","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease","volume":"34","author":"The Task Force on the management of stable coronary artery disease of the European Society of Cardiology","year":"2013","journal-title":"Eur Heart J"},{"key":"2022102606370370000_ehx178-B22","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"2022102606370370000_ehx178-B23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/1744-9987.12056","article-title":"Proteomic analysis of proteins eliminated by low-density lipoprotein apheresis","volume":"18","author":"Yuasa","year":"2014","journal-title":"Ther Apher Dial"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/20\/1561\/46637130\/eurheartj_38_20_1561.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/20\/1561\/46637130\/eurheartj_38_20_1561.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T06:37:34Z","timestamp":1666766254000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/38\/20\/1561\/3769283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,26]]},"references-count":23,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2017,4,26]]},"published-print":{"date-parts":[[2017,5,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehx178","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5,21]]},"published":{"date-parts":[[2017,4,26]]}}}